BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial
By Dr. Matthew Watson
The California stem cell agency said
today it does not plan to reactivate the $25 million loan to assist
in Geron's spinal injury clinical trial despite an impending deal that would turn the effort over to BioTime, Inc.
Kevin McCormack, senior director for
public communications for the agency, said BioTime will have to
compete in an upcoming award round if it wants to win California
dollars.
public communications for the agency, said BioTime will have to
compete in an upcoming award round if it wants to win California
dollars.
Responding to a question from the
California Stem Cell Report, McCormack said,
California Stem Cell Report, McCormack said,
“That (earlier) loan was specific to
Geron and when the trial was ended the loan ended too. Of course if
Biotime and Geron do complete their deal then Biotime would be free
to apply to us for a new disease team grant.”
McCormack later added that BioTime
could also compete in other appropriate rounds, including the
strategic partnership round just posted by CIRM. It provides for four
awards of up to $15 million. Funding could come as early as October
of next year. The strategic partnership round is a business-friendly
effort that is aimed at attracting “industry engagement and
investment.” The deadline for letters of intent is Dec. 18.
could also compete in other appropriate rounds, including the
strategic partnership round just posted by CIRM. It provides for four
awards of up to $15 million. Funding could come as early as October
of next year. The strategic partnership round is a business-friendly
effort that is aimed at attracting “industry engagement and
investment.” The deadline for letters of intent is Dec. 18.
The stem cell agency made its $25
million loan to Geron in 2011 just a few months before the Menlo Park
firm abandoned its human embryonic stem cell trial for financial
reasons. (The full text of the loan agreement can be found here.) The company has repaid the loan with interest.
million loan to Geron in 2011 just a few months before the Menlo Park
firm abandoned its human embryonic stem cell trial for financial
reasons. (The full text of the loan agreement can be found here.) The company has repaid the loan with interest.
The company has tried to sell the
assets associated with the clinical trial since last November. The only public
interest that has surfaced has come from BioTime, Inc., of Alameda,
Ca. Michael West, founder of Geron, is the CEO of BioTime. Tom
Okarma, CEO of Geron from 1999 to 2011, is CEO of the BioTime
subsidiary that would assume the clinical trial.
assets associated with the clinical trial since last November. The only public
interest that has surfaced has come from BioTime, Inc., of Alameda,
Ca. Michael West, founder of Geron, is the CEO of BioTime. Tom
Okarma, CEO of Geron from 1999 to 2011, is CEO of the BioTime
subsidiary that would assume the clinical trial.
News from clinical trial is expected to
be published soon, according to a story in the San Francisco Business
Times by Ron Leuty. He quoted CIRM President Alan Trounson as saying
that “some findings” from the trial would be published next month
in a medical journal.
be published soon, according to a story in the San Francisco Business
Times by Ron Leuty. He quoted CIRM President Alan Trounson as saying
that “some findings” from the trial would be published next month
in a medical journal.
Geron's stock traded at $1.24 at the
time of this writing today, up from $1.21 yesterday. BioTime's stock
stood at $2.99, up from $2.97.
time of this writing today, up from $1.21 yesterday. BioTime's stock
stood at $2.99, up from $2.97.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DS-6n2DoRy0/biotime-will-have-to-compete-for.html
Related Post
- Tracking the Fruits of California Stem Cell Agency Research - September 1st, 2013
- UCLA Snags $3.6 Million from California Stem Cell Agency - September 1st, 2013
- Stem Cell Agency Seeks Stronger Ties with Possible Industry Funding Partners - September 1st, 2013
- UCLA Takes Four of 13 Awards Today; One Business Wins - September 1st, 2013
- $41 Million in California Stem Cell Grants Virtually Approved - September 1st, 2013
- Stem Cell Agency Pays Tribute to the Late Duane Roth - September 1st, 2013
- Skin in California’s Stem Cell Game - September 1st, 2013
- California Stem Cell Agency's $150,000 Search for Its Financial Future - August 25th, 2013
- California Stem Cell Researchers to Receive $70 Million Next Week - August 25th, 2013
- Flim-Flam Stem Cell Artists Targeted by CIRM - August 25th, 2013
- California Stem Cell Agency Spending: Where the Money Is Going - August 25th, 2013
- A $2 Million Bill: Outside Contracting by California Stem Cell Agency - August 25th, 2013
- New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency - August 25th, 2013
- Bonilla: Veto of Pay-for-Eggs Bill Shows Troubling Mindset - August 18th, 2013
- 'Butter and Eggs Money" and a Gubernatorial Veto - August 18th, 2013
- California Gov. Jerry Brown Vetoes Pay-for-Eggs Legislation - August 18th, 2013
- A $6 Billion Question: Progress of the California Stem Cell Agency - August 18th, 2013
- Duane Roth: Ecumenical Innovator for San Diego and Biotech - August 18th, 2013
- Stem Cell Agency's Duane Roth Eulogized at Memorial Services - August 18th, 2013
- 'Paradigm Shift' -- Researchers as Patient Advocates? - August 18th, 2013
- California Stem Cell Agency on Lacks: Informed Consent Cannot Remove All Questions - August 11th, 2013
- Californians Top List of Stem Cell Honorees - August 11th, 2013
- The Henrietta Lacks Story and Eggs, Money and Motherhood - August 11th, 2013
- Skloots, Collins and More on Henrietta Lacks' Cell Line Deal - August 11th, 2013
- Memorial Services Friday for Duane Roth, Co-vice chairman of the California Stem Cell Agency - August 11th, 2013
- CIRM's Roth Dies Following Bike Accident - August 11th, 2013
- Pay-for-Eggs Legislation Now Before California Gov. Jerry Brown - August 4th, 2013
- Comment re Pay-for-Eggs Item and Forbes Article - August 4th, 2013
- Pay-for-Eggs Legislation: A Comment on Risk - August 4th, 2013
- Skimpy Coverage of Alpha Clinic Concept Approval - August 4th, 2013
- California Stem Cell Agency Looking for New Home in Two Years - August 4th, 2013
- California Stem Cell Official Duane Roth in Improving Condition - July 28th, 2013
- Another $23 Million to Recruit Star Stem Cell Scientists to California - July 28th, 2013
- California Stem Cell Agency Launches $70 Million Alpha Stem Cell Clinic Project - July 28th, 2013
- Coming Up: Live Coverage of Today's California Stem Cell Meeting - July 28th, 2013
- Stem Cell Lines and Paid-for Eggs: Stem Cell Agency Delays Action on Easing Restrictions - July 28th, 2013
- $70 Million Alpha Stem Cell Clinic Project Garners Mainstream Media Attention - July 28th, 2013
- UCLA Researcher Calls for Easing of Restrictions on Stem Cell Lines Derived from Eggs From Paid Providers - July 28th, 2013
- California Stem Cell Agency to Commit 20 Percent of Remaining Cash - July 21st, 2013
- Paying for Human Eggs, Ivan Illich and Jerry Brown - July 21st, 2013
- California's $70 Million 'Alpha' Stem Cell Clinic Plan Headed for Approval Next Week - July 21st, 2013
- TV News Piece on Pay-for-Eggs Airs in Los Angeles, San Francisco - July 14th, 2013
- Shestack Resignation Letter: Heartfelt and Eloquent - July 14th, 2013
- Veto Campaign Launched on California Pay-For-Eggs Bill - July 14th, 2013
- Sacramento Mental Health Advocate Appointed to Stem Cell Agency Board - July 14th, 2013
- California Stem Cell Merger: Capricor and Niles Therapeutics - July 14th, 2013
- Pay-for-Eggs Legislation: Strange Bedfellows and Existential Questions - July 14th, 2013
- "Comfort News" for California's Stem Cell Research Effort - July 14th, 2013
- HIV Clinical Trial Hailed by California Stem Cell Agency - July 14th, 2013
- Eggs and Cash: Stem Cell Agency Considering Easing Restrictions on Stem Cell Lines Derived Using Payments - July 14th, 2013
- California Legislation Removing Ban on Payments for Eggs for Research Heads to Governor - July 14th, 2013
- California Legislation, Human Egg Sales and Profits - July 7th, 2013
- Challenge to WARF hESC Patents Cites Recent U.S. Supreme Court Decision - July 7th, 2013
- Cost of a Stem Cell Therapy? An Estimated $512,000 - June 30th, 2013
- Bluebird and Banking: Media Pluses for California Stem Cell Agency - June 30th, 2013
- International team submits IND application - June 23rd, 2013
- Pay-For-Eggs Legislation Draws More Media Attention - June 23rd, 2013
- Compensation for Human Eggs Approved by Key California Senate Committee, But Not For CIRM Researchers - June 16th, 2013
- Merksamer Makes Only Bid For Stem Cell Agency Lobbying Contract - June 16th, 2013
- Cellular Dynamics: California Stem Cell Agency Recipient Plans $57 Million IPO - June 9th, 2013
- Light Coverage of Cellular Dynamics IPO But One Exec Says It's Good for Stem Cell Biz - June 9th, 2013
- Pomeroy on Doing the Right Thing and Foster Care - June 9th, 2013
- Vatican Funding for California Stem Cell Agency? - June 2nd, 2013
- Bluebird bio of Massachusetts Still Waiting for California Stem Cell Money - June 2nd, 2013
- California's Alpha Stem Cell Clinics: Open in 2014, Six to Eight Locations - June 2nd, 2013
- Monterey Newspaper Chides California Stem Cell Agency - June 2nd, 2013
- Trounson Proposes $70 Million, Fast-Track Stem Cell Clinic Plan for California - June 2nd, 2013
- $70 Million Alpha Stem Cell Clinic Proposal Draws Reader Comment - June 2nd, 2013
- Sacramento Bee: Ongoing Conflict Problems No Help for Future Funding of Stem Cell Agency - June 2nd, 2013
- Multimillion Dollar Carrots for Stem Cell Research in California - May 26th, 2013
- California Stem Cell Agency: 5 Percent Budget Increase for Coming Fiscal Year - May 26th, 2013
- $36 Million Recruitment: Names of Researchers Being Lured to California - May 26th, 2013
- Stem Cell Agency Approves $36 million to Recruit Six Scientists to California - May 26th, 2013
- California Stem Cell Agency to Court Patient Groups This Summer - May 26th, 2013
- Nature Reports on Lee Hood Conflict Case - May 26th, 2013
- Grant Reviewer Conflict in $40 Million Round at California Stem Cell Agency - May 26th, 2013
- Text of CIRM Comments on Lee Hood Questions - May 26th, 2013
- Replicating Oregon Cloning in California: Views on the Legality - May 19th, 2013
- Oregon-style Stem Cell Cloning Research Illegal in California: No Pay for Eggs in Golden State - May 19th, 2013
- Weissman Says Oregon-style Stem Cell Research Could be Done in California - May 19th, 2013
Stem Cell Therapy
Comments Off on BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial |
November 18th, 2012
This author published 5852 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research